{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:27:12Z","timestamp":1761676032698},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.humpath.2012.10.027","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T11:27:05Z","timestamp":1361446025000},"page":"1421-1428","source":"Crossref","is-referenced-by-count":9,"title":["Molecular markers of therapeutic resistance in breast cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Ling","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2012.10.027_bb0005","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/annonc\/mdp492","article-title":"Triple-negative breast cancer\u2014current status and future directions","volume":"20","author":"Gluz","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2012.10.027_bb0010","first-page":"696208","article-title":"Triple-negative breast cancer: adjuvant therapeutic options","volume":"2011","author":"Gucalp","year":"2011","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.humpath.2012.10.027_bb0015","series-title":"Global Cancer Facts & Figures 2007","author":"Garcia","year":"2007"},{"key":"10.1016\/j.humpath.2012.10.027_bb0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-1293-1","article-title":"Triple negative breast cancer: unmet medical needs","volume":"125","author":"Pal","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2012.10.027_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.NPR.0000407602.29522.d7","article-title":"Breast cancer: overview & updates","volume":"36","author":"Downs-Holmes","year":"2011","journal-title":"Nurse Pract"},{"key":"10.1016\/j.humpath.2012.10.027_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13148-011-0040-8","article-title":"MicroRNA-mediated drug resistance in breast cancer","volume":"2","author":"Kutanzi","year":"2011","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.humpath.2012.10.027_bb0035","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/s00280-003-0624-x","article-title":"Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms","volume":"52","author":"Senderowicz","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.humpath.2012.10.027_bb0040","doi-asserted-by":"crossref","first-page":"e15630","DOI":"10.1371\/journal.pone.0015630","article-title":"Markers of tumor-initiating cells predict chemoresistance in breast cancer","volume":"5","author":"Gong","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2012.10.027_bb0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000336078","article-title":"Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome","volume":"82","author":"Hashimoto","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.humpath.2012.10.027_bb0050","first-page":"457","article-title":"Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB","volume":"31","author":"Zatelli","year":"2009","journal-title":"Cell Oncol"},{"key":"10.1016\/j.humpath.2012.10.027_bb0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1677\/ERC-07-0114","article-title":"Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression","volume":"14","author":"Zatelli","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.humpath.2012.10.027_bb0060","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-008-0229-5","article-title":"Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study","volume":"116","author":"Falandry","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2012.10.027_bb0065","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5","article-title":"Expression of drug resistance proteins in breast cancer, in relation to chemotherapy","volume":"71","author":"Linn","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2012.10.027_bb0070","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1038\/sj.onc.1206394","article-title":"HER2\/PI-3K\/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells","volume":"22","author":"Knuefermann","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2012.10.027_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2325\/jbcs.13.137","article-title":"Activation of PI3K\/Akt signaling and hormone resistance in breast cancer","volume":"13","author":"Tokunaga","year":"2006","journal-title":"Breast Cancer"},{"key":"10.1016\/j.humpath.2012.10.027_bb0080","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/1078-0432.CCR-07-1046","article-title":"Down-regulation of phosphatidylinositol 3\u2032-kinase\/AKT\/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer","volume":"14","author":"Generali","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.10.027_bb0085","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1158\/1078-0432.CCR-06-0725","article-title":"Overexpression of caspase-3s splice variant in locally response to neoadjuvant chemotherapy advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy","volume":"12","author":"V\u00e9gran","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.10.027_bb0090","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1038\/modpathol.2010.36","article-title":"Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale","volume":"23","author":"Weaver","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2012.10.027_bb0095","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nm.2385","article-title":"Caspase 3\u2013mediated stimulation of tumor cell repopulation during cancer radiotherapy","volume":"17","author":"Huang","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2012.10.027_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/scd.2008.0055","article-title":"ALDH1 as a functional marker of cancer stem and progenitor cells","volume":"18","author":"Douville","year":"2009","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.humpath.2012.10.027_bb0105","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1158\/1078-0432.CCR-08-1479","article-title":"Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers","volume":"15","author":"Tanei","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.10.027_bb0110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.humpath.2012.04.014","article-title":"Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma","volume":"44","author":"Luo","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2012.10.027_bb0115","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.1158\/0008-5472.CAN-06-1215","article-title":"Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation","volume":"66","author":"Das","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2012.10.027_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/bjc.2011.204","article-title":"A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer","volume":"105","author":"Glover","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2012.10.027_bb0125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1477-7819-9-46","article-title":"CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion","volume":"9","author":"Johnson-Holiday","year":"2011","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.humpath.2012.10.027_bb0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1139\/o06-072","article-title":"GammaH2AX and its role in DNA double-strand break repair","volume":"84","author":"Fillingham","year":"2006","journal-title":"Biochem Cell Biol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817712004480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817712004480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T10:24:56Z","timestamp":1539858296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817712004480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0046817712004480"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2012.10.027","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}